C4 Therapeutics, Inc.

NASDAQ:CCCC

1.54 (USD) • At close April 25, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024202320222021202020192018
Revenue 35.58420.75631.09645.78533.19521.38119.364
Cost of Revenue 0117.7067.5722.90777.46847.66428.592
Gross Profit 35.584-96.9523.52442.878-44.273-26.283-9.228
Gross Profit Ratio 1-4.6710.7560.937-1.334-1.229-0.477
Reseach & Development Expenses 110.637117.706117.84194.66578.4448.05928.592
General & Administrative Expenses 42.12442.08142.78933.25415.2048.7747.161
Selling & Marketing Expenses 0000000
SG&A 42.12442.08142.78933.25415.2048.7747.161
Other Expenses 2.43700000.325-0.007
Operating Expenses 155.198159.787160.63127.91993.64456.83335.753
Operating Income -119.614-139.031-129.534-82.134-60.449-35.452-16.389
Operating Income Ratio -3.361-6.698-4.166-1.794-1.821-1.658-0.846
Total Other Income Expenses Net 14.4297.8181.359-1.758-6.5122.1570.678
Income Before Tax -105.185-131.213-128.175-83.892-66.961-33.295-15.711
Income Before Tax Ratio -2.956-6.322-4.122-1.832-2.017-1.557-0.811
Income Tax Expense 0.1311.28-1.6762.145-0.6260.8040.678
Net Income -105.316-132.493-126.499-86.037-66.335-34.099-15.711
Net Income Ratio -2.96-6.383-4.068-1.879-1.998-1.595-0.811
EPS -1.52-2.67-2.59-1.87-1.54-0.79-1.06
EPS Diluted -1.52-2.67-2.59-1.87-1.54-0.79-1.06
EBITDA -103.367-122.103-124.283-78.84-62.891-30.556-15.116
EBITDA Ratio -2.905-5.883-3.997-1.722-1.895-1.429-0.781